Top in cardiology: ACE inhibitors, ARBs and COVID-19, women at higher risk for CVD

A study that indicated using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers was not linked to an increased rate of COVID-19 infection or mortality was the top story in cardiology last week.

Tips on identifying which women may be at greater risk for CVD was another top story.

Read these and other top stories in cardiology below.

ACE inhibitors, ARBs do not pose additional risk in COVID-19 in two meta-analyses

Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers was not associated with an increased rate of COVID-19 infection or mortality, data from two meta-analyses showed. Read more.

Menopausal transition heralds elevated CV risk; early prevention is vital

During the menopausal transition, women have an increased prevalence of cardiometabolic and CV risk factors; however, data on early preventive strategies are lacking, according to a new statement from the American Heart Association. Read more.

In-hospital outcomes similar with milrinone, dobutamine for treatment of cardiogenic shock

Data from the CAPITAL Do-Re-Mi trial indicated there were no difference in outcomes in patients treated with the widely used agents milrinone and dobutamine for in-hospital treatment of cardiogenic shock. Read more.

Benefits of dapagliflozin consistent in CKD, regardless of concomitant CVD

The benefits of dapagliflozin remain consistent in patients with chronic kidney disease, with and without type 2 diabetes, independent of baseline CV status, according to an analysis of the DAPA-CKD trial. Read more.

More than 20% of racial disparities in hypertension related to treatment intensification

At least one-fifth of racial disparities in hypertension treatment may stem from racial inequities in treatment intensification, study results suggested. Read more.